Prognostic value of CD47 overexpression measured by flow cytometry in acute myeloid leukemia
Annals of Hematology · 2025
DOI: 10.1007/s00277-025-06401-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2025. Verfasst von Vincenzo Sammartano und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Department of Medical Science, Surgery and Neurosciences, AOUS Policlinico Le Scotte, University of Siena, Siena, Italy. Hauptthemen laut MEDLINE: CD47 Antigen, Leukemia, Myeloid, Acute, Flow Cytometry. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Siena.
Abstract (Originalsprache)
The glycoprotein CD47 is an innate immune checkpoint ubiquitously expressed on all healthy cells to prevent themselves from phagocytosis. CD47 binds to its receptor SIRPα on macrophages, thus producing a signal transduction cascade which inhibits phagocytosis. CD47 is overexpressed on various solid and hematologic malignancies in order to escape the immune system. High expression of CD47 in patients with AML has been associated with poor prognosis, however, there is no standard technique to assess CD47 expression on AML blasts in clinical practice and the real prognostic value of CD47 overexpression varies among studies in the current literature. In this study, CD47 expression was evaluated by flow cytometry on AML blasts from bone marrow samples at diagnosis and reported in terms of median fluorescence intensity (MFI). Flow cytometry analysis demonstrated the expression of CD47 in all AML patients with a median MFI on leukemic blasts of 16.8 (range 2–693.63). CD47 levels on AML blasts correlated with WBC count (rs 0.403, p = 0.016), BM blasts percentage (rs 0.494, p = 0.003), PB blasts percentage (rs 0.482, p = 0.003) and LDH levels (rs 0.382, p = 0.028) and higher expression of CD47 was associated with reduced survival with a hazard ratio of 1.04 (CI: 1.01–1.08, p = 0.047). Further studies with larger sample sizes are necessary to better define the real prognostic value of CD47 overexpression in the complexity of AML tumor microenvironment and, possibly, to identify a subgroup of patients who could derive maximum benefit from emerging CD47-SIRPα blocking therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Unit, Department of Medical Science, Surgery and Neurosciences, AOUS Policlinico Le Scotte, University of Siena, Siena, Italy.
- Department of Clinical Medicine and Surgery, Hematology Section, University of Naples Federico II, Naples, Italy.
- Hematology Unit, Department of Medical Science, Surgery and Neurosciences, AOUS Policlinico Le Scotte, University of Siena, Siena, Italy. sicuranza4@unisi.it.
- Department of Medical Science, Surgery and Neurosciences, University of Siena, Siena, Italy.
Förderung
- Università degli Studi di Siena
Zitieren
APA
Sammartano, V., Sicuranza, A., Pacelli, P., Bestoso, E., Santoni, A., Brambilla, C. Z., Defina, M., Cartocci, A., Raspadori, D., & Bocchia, M. (2025). Prognostic value of CD47 overexpression measured by flow cytometry in acute myeloid leukemia. Annals of Hematology. https://doi.org/10.1007/s00277-025-06401-2
Vancouver
Sammartano V, Sicuranza A, Pacelli P, Bestoso E, Santoni A, Brambilla CZ, et al. Prognostic value of CD47 overexpression measured by flow cytometry in acute myeloid leukemia. Annals of Hematology. 2025. doi:10.1007/s00277-025-06401-2
BibTeX
@article{Sammartano2025,
author = {Sammartano, Vincenzo and Sicuranza, Anna and Pacelli, Paola and Bestoso, Elena and Santoni, Adele and Brambilla, Corrado Zuanelli and Defina, Marzia and Cartocci, Alessandra and Raspadori, Donatella and Bocchia, Monica},
title = {Prognostic value of CD47 overexpression measured by flow cytometry in acute myeloid leukemia},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-025-06401-2}
}
EUVIMED